Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT05248256
Official study title

Vertebral Marrow Attention Trial (VMAT)

Study summary

The purpose of this study is to see whether designing radiation to spare the vertebral bone marrow can limit the rates of lymphopenia during standard of care chemoradiation therapy and in the time to count recovery in the ensuing weeks. Secondary endpoints will examine whether this leads to improved disease control whether this is predictive of improved clinical outcomes such as rates of local recurrence (LR), metastasis free survival (MFS), overall survival (OS), and progression free survival (PFS) which will be followed prospectively up to 5 years.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedEvidence-based radiation dose limitation to the vertebral bone marrow

The study team can explain what participation involves.

Who it may be forRecurrent or relapsed

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 30, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?The University of Texas Health Science Center at San Antonio

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
The University of Texas Health Science Center at San Antonio
Interventions being studied
Other: Evidence-based radiation dose limitation to the vertebral bone marrow
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Recurrent or relapsed→
Treatment approach
Radiation therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Adult patient \> 18 years
  • Patients with AJCC (American Joint Committee on Cancer) 8 T1-T4, N1-N3, M0 stage IIIA-IIIC NSCLC (non small cell lung cancer)
  • Patients with oligometastatic disease stage IV, M1 disease, in which definitive concurrent chemoradiotherapy to the thorax is planned
  • CBC/CMP within these limits
  • Absolute lymphocyte count\>500/ml
  • Hemoglobin\>8 g/dL
  • AST (aspartate aminotransferase)/ALT (alanine transaminase) \<2.5 times of ULN
  • Eastern Cooperative Oncology Group (ECOG) 0-2
Reasons someone may not be able to joinExclusion criteria
  • History of thoracic irradiation
  • History of palliative radiation for the current malignancy under consideration
  • Patients not being treated with definitive standard of care to the chest
  • History of bone marrow disease and or leukemia
  • History of prior cytotoxic chemotherapy for a disease other than for the current malignancy
  • Polymetastatic disease, defined here as ≥3 or more extrathoracic metastases
  • Administration of concurrent immunotherapy during radiation therapy, either as part of another clinical trial or otherwise

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Vanderbilt-Ingram Service for Timely AccessNashville, Tennessee
  • Mays Cancer Center, UT Health San AntonioSan Antonio, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 30, 2024. Always confirm current availability with the study team.

View original record ↗